Navamedic extends important partnership

Navamedic ASA (OSE: NAVA) today announced a five year extension of its partnership agreement with UK based Vitaflo International.  According to the agreement, Navamedic will remain Vitaflo's sole distributor for its metabolic nutrition products in the Nordic markets.

Navamedic has cooperated with Vitaflo for more than ten years. The Vitaflo products constitute Navamedic's Medical Nutrition business segment, currently representing approximately 15 per cent of the Company's sales. The specialized clinical nutrition products are used in the treatment of metabolic disorders and by patients with specific nutritional needs. Navamedic expects a further expansion of its medical nutrition product line in the second half of 2013.

"Our medical nutrition products have a strong position in the Nordic market, which has a 5-10 per cent annual market growth in this segment. Metabolic nutrition products are an important part of Navamedic's revenue base, as we move forward in expanding our portfolio of pharmaceutical products," said Navamedic's interim CEO Håkan Josephsson.

For further information, please call Håkan Josephsson, interim CEO, telephone +46 706 742 533 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

 Oslo, 9th of July 2013